Effect of mopidamol on survival in carcinoma of the lung and colon: final report of Veterans Administration Cooperative Study No. 188.
Mopidamol (RA-233), a derivative of dipyridamole, is a phosphodiesterase inhibitor that has been shown previously to limit progression of malignancy in certain experimental animal models and in a pilot study in humans. RA-233 plus chemotherapy was compared with chemotherapy alone in a 5-year double-blind trial involving 719 patients with advanced carcinomas of the lung and of the colon. RA-233 treatment was associated with a statistically significant prolongation of survival in patients with non-small cell lung cancer (N-SCLC) limited to one hemithorax and with reduction in mean plasma fibrogen concentration. RA-233 was not toxic. The favorable effects on survival could not be explained by any factor other than the RA-233 treatment. In other tumor categories tested, no differences in survival were observed. These results suggest that RA-233 is useful in the treatment of N-SCLC of limited extent. They also suggest that therapeutic intervention aimed at modified intracellular pathways might constitute a novel investigative approach to the treatment of cancer.
Zacharski
L R
LR
Veterans Administration (VA) Medical Center, White River Junction, VT 05001.
Moritz
T E
TE
Baczek
L A
LA
Rickles
F R
FR
Edwards
R L
RL
Forman
W B
WB
Forcier
R J
RJ
Cornell
C J
CJ
Haakenson
C M
CM
Ballard
H S
HS
D002277:Carcinoma / Q000188:drug therapy* / Q000401:mortality; D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D000242:Cyclic AMP / Q000032:analysis; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D009012:Mopidamol / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D009857:Oncogenes; D011446:Prospective Studies; D011743:Pyrimidines / Q000627:therapeutic use*; D011897:Random Allocation
D011743:Pyrimidines; D009012:Mopidamol; D000242:Cyclic AMP